Onychomycosis Market Report
Onychomycosis Market by Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, and Other Types), Treatment (Oral, Topical, and Other), and Region (North America, Europe, Asia-Pacific, and LAMEA): Opportunity Analysis and Industry Forecast, 2023-2032
Onychomycosis, often known as nail fungus, is a common fungal infection of the fingernails and toes. It is distinguished by the invasion of fungus, most commonly dermatophytes, into the nails, resulting in a variety of symptoms such as nail coloring, thickness, brittleness, and, in severe cases, pain and discomfort. Onychomycosis is a chronic and sometimes unsightly illness that is more common in elderly people and people with compromised immune systems. Walking barefoot in wet public spaces, wearing tight shoes, or having a history of fungal skin infections can all contribute to it. Onychomycosis treatment options include topical antifungal treatments, oral antifungal medications, and, in some cases, surgical excision of the infected nail.
Global Onychomycosis Market Analysis
The global onychomycosis market size was $3.5 billion in 2022 and is predicted to grow with a CAGR of 4.7%, by generating a revenue of $5.5 billion by 2032.
COVID-19 Impact on Global Onychomycosis Market
The global onychomycosis market has been significantly impacted by the COVID-19 pandemic. While onychomycosis is still a common illness, the market was impacted by decreased patient visits to healthcare facilities and clinics during the peak of the pandemic. Non-essential medical treatments were postponed, compromising onychomycosis diagnosis and treatment. Furthermore, supply chain interruptions and reduced manufacturing capacity resulted in a shortage of topical antifungal medications. However, the increasing focus on hygiene and healthcare awareness during the pandemic may fuel future market expansion as consumers seek nail health remedies. As the world recovers from the pandemic, the market for onychomycosis is likely to rebound, maybe with a greater emphasis on telemedicine and over-the-counter treatment options, reflecting shifts in healthcare delivery approaches spurred by COVID-19.
Rise of Novel and More Effective Antifungal Medicines to Drive the Market Growth
Several factors have contributed to the massive growth of the onychomycosis market. Firstly, an ageing population has resulted in a larger prevalence of this ailment, as older people are more prone to nail fungal infections. Furthermore, increasing awareness and early detection as a result of healthcare initiatives, as well as enhanced access to healthcare services, have supported market expansion. Furthermore, continued research and development efforts have resulted in the introduction of novel and more effective antifungal medicines, allowing patients to have more treatment alternatives. Finally, changing lifestyle trends such as the demand for cosmetic nail care and a greater emphasis on general health and hygiene have prompted people to seek onychomycosis treatment. These considerations have resulted in a thriving and ever-expanding market for onychomycosis therapies.
High Costs Involved in Onychomycosis Diagnosis and Treatment to Restrain the Market Growth
The onychomycosis market is dealing with a number of obstacles and barriers that hamper its growth and global expansion. Onychomycosis diagnosis and treatment can be costly, making it less accessible to some people, particularly in regions with low healthcare resources. Furthermore, the recurrent and sluggish progress of nail fungal infections can result in treatment abandonment or postponement, impeding effective treatment. Disruptions in the supply chain and regulatory difficulties can also impact the availability and approval of new antifungal medications. Finally, patient compliance with lengthy treatment regimens can be difficult, as incomplete treatment rounds may result in recurrence.
Advancements in Technology to Drive Excellent Opportunities
Technological advancements are poised to generate excellent prospects for the onychomycosis industry. Improved diagnostic tools, such as speedy and reliable diagnostic tests, will allow for early diagnosis and timely intervention, resulting in better treatment outcomes. Furthermore, technological innovation is driving research into novel antifungal agents and medication delivery methods, which holds the possibility of more effective and simple therapies. Telemedicine and digital health platforms are also important in improving access to healthcare and enabling remote monitoring of onychomycosis cases. As technology advances, novel opportunities for diagnosis, treatment, and patient care are projected to open up, ultimately adding to the growth and expansion of the onychomycosis market.
Global Onychomycosis Market Share, by Type, 2022
The distal subungual onychomycosis sub-segment accounted for the highest market share in 2022. This is due to the increasing prevalence and severity of onychomycosis. Distal subungual onychomycosis, which affects the nail plate and surrounding tissue, is one of the most frequent types of onychomycosis, accounting for a sizable proportion of all identified cases. Its difficult-to-treat characteristic sometimes needs longer treatment regimens, which contribute to increased market revenues. Furthermore, rising awareness of onychomycosis, as well as developments in diagnosis and treatment options for this subtype, have increased its commercial relevance. These variables combined to drive distal subungual onychomycosis to the top of the onychomycosis market in 2022.
Global Onychomycosis Market Share, by Treatment, 2022
The topical sub-segment accounted for the highest market share in 2022. Topical therapies, such as medicated nail lacquers and lotions, are often utilized as first-line therapy due to their convenience of use, low adverse effects, and non-invasive nature. Both patients and physicians prefer them for mild to moderate cases of onychomycosis. Furthermore, advances in topical formulations have resulted in more effective and convenient choices, which has increased their popularity. As access and awareness of these therapies grow, particularly in the over-the-counter (OTC) market, the topical sub-segment continues to dominate, providing a practical and accessible solution to a wide spectrum of patients suffering from nail fungal infections.
Global Onychomycosis Market Share, by Region, 2022
The North America onychomycosis market generated the highest revenue in 2022. North America is important to the market for onychomycosis since it contributes significantly to the growth and income of the sector. Millions of people in the area suffer from onychomycosis, sometimes known as toenail fungus or fingernail fungus. Numerous variables, such as lifestyle choices, population ageing, the incidence of diabetes, and increased nail health awareness, are blamed for the disease's high prevalence. The rising need for efficient treatment options is one of the main factors driving the onychomycosis market in North America. Additionally, North America has a strong healthcare infrastructure and significant healthcare spending. Better access to healthcare facilities is made possible as a result, making it simpler for people to get Onychomycosis treatment alternatives and seek medical help. Additionally, the area is home to several significant pharmaceutical and biotechnology firms that make significant investments in the creation and marketing of treatments for onychomycosis. Their market presence has a big impact on the availability and promotion of different drugs and therapeutic options. The regulatory landscape in North America also has a significant impact on how the market for onychomycosis is shaped. Building confidence among consumers and healthcare professionals, stringent regulatory requirements and rigorous approval procedures guarantee that only safe and effective treatments are made available to patients. Onychomycosis education and awareness programmes are also widely used in the area, which helps to raise knowledge of the condition and promote early detection and treatment. These initiatives assist in easing the condition's burden and enhancing patient outcomes.
Competitive Scenario in the Global Onychomycosis Market
Investment and agreement are common strategies followed by major market players. Leading pharmaceutical companies are actively investing in R&D to develop new treatments, with an emphasis on improving the efficacy and patient-friendliness of existing drugs. Collaborations and partnerships are also taking place in the market between pharmaceutical companies, diagnostic businesses, and healthcare providers in order to streamline patient care. Some of the leading onychomycosis market players are Bausch Health Companies Inc., GSK plc, Abbott, Pfizer Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Cipla Inc., Merck & Co., Inc., Novartis AG, and Sun Pharmaceutical Industries Ltd.
Historical Market Estimations
Base Year for Market Estimation
Forecast Timeline for Market Projection
North America, Europe, Asia-Pacific, and LAMEA
Segmentation by Type
Segmentation by Treatment
Key Companies Profiled
Q1. What is the size of the global onychomycosis market?
A. The size of the global onychomycosis market was over $3.5 billion in 2022 and is projected to reach $5.5 billion by 2032.
Q2. Which are the major companies in the onychomycosis market?
A. Bausch Health Companies Inc. and GSK plc are some of the key players in the global onychomycosis market.
Q3. What are the strategies opted by the leading players in this market?
A. Agreement and investment are the two key strategies opted for by the operating companies in this market.
Q4. Which companies are investing more in R&D practices?
A. GSK plc, Abbott, Pfizer Inc. and Bayer AG are the companies investing more in R&D activities for developing new products and technologies.